HUMAN HEALTH

ENVIRONMENTAL HEALTH

CONGENITAL ADRENAL HYPERPLASIA SCREENING

NEW
Increased Specificity and Improved Precision

PerkinElmer's Neonatal 17 α-OH-Progesterone (17OHP) assay for its DELFIA® and AutoDELFIA® platforms provides the highest standards of reliability and safety in screening for congenital adrenal hyperplasia (CAH). It is globally the most widely used assay for 1st tier CAH screening, and in 2008 the product was used in 47 countries.

Accurate CAH screening with choice of protocols

The analytical sensitivity in both AutoDELFIA and manual DELFIA is 0.5 ng/mL serum. Intra-assay imprecision is close to 6% for both assays. All kit controls and calibrators are lot-specific to ensure that every lot is of the same level. The manual 17OHP assay may be run with 3 hour or overnight incubations to meet different customer needs.

No extraction step needed

The assay is a straightforward dried blood spot assay. No extraction step is needed, which means savings in both total assay time and materials.

DELFIA®-technology stands for quality

The unique fluorescent properties of lanthanide chelates are the basis for high sensitivity and low assay variation, and these features, in turn, stand for reliable and accurate 17a-OH-Progesterone measurement with low bias.

Early diagnosis for early disease intervention

Congenital adrenal hyperplasia is a genetic disorder affecting 1:10,000 to 1:15,000 newborns worldwide and the most severe form of the disease can lead to a life-threatening condition during the first weeks of life. The disease is caused by enzyme defects in the steroid biosynthesis, the most frequent types being 21- and 11a-hydroxylase deficiency. In both of these the 17α-OH-progesterone, a precursor for cortisol, is increased which makes its determination a useful screening method for 95% of all of the CAH cases.

PerkinElmer's Neonatal 17OHP assay is intended for the quantitative determination of 17α-OH-progesterone in dried blood spot specimens as an aid in screening newborns for CAH.

Quality right from the start

PerkinElmer®
For the Better



Robust competitive type DELFIA® assay

The AutoDELFIA/DELFIA Neonatal 17OHP assay is based on the competitive binding of europium-labeled 17OHP, and 17OHP in the sample to 17OHP-specific antibodies.

ORDERING INFORMATION

A024-104	DELFIA® Neonatal 17α-OH-progesterone (17OHP) (4 plates)
B024-104	AutoDELFIA® Neonatal 17α-OH-progesterone (17OHP) (4 plates)
A024-110	DELFIA® Neonatal 17α-OH-progesterone (17OHP) (10 plates)
B024-112	AutoDELFIA® Neonatal 17α-OH-progesterone (17OHP) (12 plates)

All PerkinElmer neonatal products may not be available in all countries.

For more information please talk to your local PerkinElmer representative, www.perkinelmer.com/ContactUs

PerkinElmer, Inc.
940 Winter Street
Waltham, MA 02451 USA
Phone: (800) 762-4000 or
(+1) 203-925-4602
www.perkinelmer.com

PerkinElmer Genetic Screening
Center of Excellence
Wallac Oy, PO Box 10
20101 Turku, Finland
Phone: + 358 2 2678 111
Fax: + 358 2 2678 357

For a complete listing of our global offices, visit www.perkinelmer.com/ContactUs

1244-9835-02, September 2009 Printed in Finland